Vasopressin (Vasostrict/Pitressin)

Peptide

Vasopressin (arginine vasopressin, AVP) is a nonapeptide hormone. FDA-approved in 2014 for vasodilatory shock (septic shock, post-cardiotomy). VASST trial (NEJM 2008, n=778) showed mortality benefit in less severe septic shock (26.5% vs 35.7%, p=0.05). Allows reducing norepinephrine requirements. Dose: 0.01-0.1 units/minute. Surviving Sepsis Campaign recommends adding AVP when NE ≥0.25-0.50 µg/kg/min.

Quick Answer

What it is

Vasopressin (arginine vasopressin, AVP) is a nonapeptide hormone. FDA-approved in 2014 for vasodilatory shock (septic shock, post-cardiotomy).

Key findings

Grade A: Blood Pressure Support (Vasodilatory Shock)
Grade A: Norepinephrine Sparing (Vasodilatory Shock)
Grade A: Mortality (Less Severe Sepsis) (Vasodilatory Shock)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Vasopressin (Vasostrict/Pitressin)

Quick Facts: Vasopressin (Vasostrict/Pitressin)

Best Evidence:Grade A
Conditions Studied:1
Research Outcomes:11
Grade A Findings:4
Key Effect:Vasodilatory Shock

1 conditions · 11 outcomes

Detailed Outcomes

Blood Pressure Support

FDA-approved for maintaining blood pressure in vasodilatory shock. MAP significantly higher at 24h with AVP+NE vs NE alone.

large↑Improves

Norepinephrine Sparing

Significantly reduces norepinephrine dose requirements at 24 and 48 hours. Allows weaning of catecholamines.

large↓Improves

Mortality (Less Severe Sepsis)

VASST trial: 28-day mortality 26.5% vs 35.7% (p=0.05) in less severe septic shock. No benefit in more severe shock.

moderate↓Improves

Hemodynamic Stabilization

Heart rate lower at 24-48h with AVP. Effective even in catecholamine-resistant vasodilatory shock.

large↑Improves

Blood Glucose Control

10 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.

moderate↓Improves

Kidney Function

7 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.

small↑Improves

Cardiac Protection

4 human trials support this finding. Human clinical trial data available.

small↑Improves

Sepsis Outcomes

3 preclinical studies support this finding. Primarily preclinical evidence.

small↓Improves

Reproductive Outcomes

3 human trials support this finding. Human clinical trial data available.

small↑Improves

Sleep Quality

2 preclinical studies support this finding. Primarily preclinical evidence.